LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
24,905,500
21,493,300
22,871,300
21,222,100
Cost of Revenue
6,316,800
4,681,700
6,070,200
5,654,900
Gross Profit
18,588,700
16,811,600
16,801,100
15,567,200
Operating Expenses
Research Development
5,661,300
5,051,200
5,281,800
5,243,900
Selling General and Administrative
6,639,300
5,975,100
6,588,100
6,452,000
Total Operating Expenses
12,300,600
11,026,300
11,869,900
11,695,900
Operating Income or Loss
6,288,100
5,785,300
4,931,200
3,871,300
Interest Expense
391,500
272,100
225,000
185,200
Total Other Income/Expenses Net
-1,356,300
-2,105,200
-2,676,100
-420,800
Income Before Tax
4,650,000
3,680,100
2,197,400
3,374,000
Income Tax Expense
305,000
529,500
2,401,500
636,400
Income from Continuing Operations
4,345,000
3,150,600
-204,100
2,737,600
Net Income
7,947,700
3,232,000
-204,100
2,737,600
Net Income available to common shareholders
7,947,700
3,232,000
-204,100
2,737,600
Reported EPS
Basic
-
3.14
-0.19
2.49
Diluted
-
3.13
-0.19
2.49
Weighted average shares outstanding
Basic
-
1,027,721
1,052,023
1,100,875
Diluted
-
1,033,667
1,052,023
1,100,875
EBITDA
-
7,394,300
4,931,200
3,871,300